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Sir: As ovaries are the target organs of gonadotropins, a
relationship with the development or growth of ovarian
cancer has been postulated.1 However, there are few
data, obtained with small patient numbers, for follicle-
stimulating hormone (FSH) receptor (FSH-R) and lutein-
izing hormone (LH) receptor (LH-R) expression in ovar-
ian cancer tissue, and hardly any data on their prognostic
relevance. Therefore, we conducted this study to quantify
LH-R and FSH-R expression in ovarian cancer tissue and
to analyse their impact on relapse and survival.
Immunohistochemical (IHC) staining was performed
for LH-R and FSH-R expression in 156 ovarian cancer
tissue samples. Most patients presented with advanced
Table 1. Patient characteristics
Patients (n) 156























Median overall survival (a)
[years (range)]
5.9 (0.3–16.6)
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Table 2. Follicle-stimulating hormone receptor (FSH-R) and
luteinizing hormone receptor (LH-R) staining in relation to











I 13 (37.1) 22 (62.9) 11 (31.4) 24 (68.6)
II 1 (11.1) 8 (88.9) 5 (55.6) 4 (44.4)
III 42 (38.5) 67 (61.5) 39 (35.8) 70 (64.2)
IV 0 (0) 2 (100.0) 0 (0) 2 (100.0)
Nodal status
Negative 17 (39.5) 26 (60.5) 15 (34.9) 28 (65.1)
Positive 19 (36.5) 33 (63.5) 13 (25.0) 39 (75.0)
Grading
Low 16 (41.0) 23 (59.0) 15 (38.5) 24 (61.5)
Intermediate 18 (33.3) 36 (66.7) 15 (27.8) 39 (72.2)
High 17 (32.1) 36 (67.9) 25 (47.2) 28 (52.8)
Histological subtype
Serous 39 (35.5) 71 (64.5) 42 (38.2) 68 (61.8)
Endometrioid 8 (38.1) 13 (61.9) 5 (23.8) 16 (76.2)
Mucinous 5 (41.7) 7 (58.3) 3 (25.0) 9 (75.0)
Clear cell 5 (38.5) 8 (61.5) 5 (38.5) 8 (61.5)
Table 3. Correlation analysis for follicle-stimulating hormone receptor (FSH-R) and luteinizing hormone receptor (LH-R) for






Correlation coefficient 0.108 0.012 )0.091 )0.081 1.000 0.220**
Sigma (two-sided) 0.289 0.885 0.274 0.314 0.006
N 95 155 146 156 156 156
FSH-R
Correlation coefficient 0.031 )0.024 0.069 –0.035 0.220** 1.000
Sigma (two-sided) 0.767 0.767 0.405 0.663 0.006
N 95 155 146 156 156 156























Figure 1. Representative slides of immunohistochemical staining for
the luteinizing hormone receptor (LH-R) and follicle-stimulating
hormone receptor (FSH-R) for serous, endometrioid, clear cell and
mucinous ovarian cancer. No FSH-R or LH-R immunoreactivity was
detected in tumour stroma (magnification ·20).
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disease at primary diagnosis (Table 1). The median
follow-up time was 7.3 years (range 0.3–16.8 years),
with 26 documented relapses and 91 deaths. The
median relapse-free survival was 2.1 years (range 0.9–
7.2 years) and the median overall survival was


































Figure 2. Luteinizing hormone receptor (LH-R) and follicle-stimulating hormone receptor (FSH-R) expression in low-grade (G1), intermediate




































Figure 3. Luteinizing hormone receptor (LH-R) and follicle-stimulating hormone receptor (FSH-R) expression in relation to tumour stage: early
ovarian cancer (EOC) versus advanced ovarian cancer (POC) of different histological subtypes.
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Ovarian cancer tissue analysis revealed LH-R-posi-
tive and FSH-R-positive tumours in 64.3% and 63.1%
of samples, respectively (Figure 1). Only slight differ-
ences in LH-R or FSH-R expression could be observed
with respect to histological subtype, grade or tumour
stage (Table 2). Correlation analysis showed no signif-
icant correlation between LH-R or FSH-R and other
histological parameters (P > 0.05), whereas a correla-
tion between LH-R and FSH-R could be identified
(P = 0.006, Spearman rho; Table 3). In general,
statistical analysis for the immunoreactive score
staining yielded no other correlations, but subgroup
analysis indicated some significant differences in recep-
tor expression (Figures 2 and 3).
Kaplan–Meier analysis revealed a poor prognosis in
ovarian cancer patients whose tumour was solely
FSH-R-positive. In contrast, good overall survival was
observed for those who showed sole LH-R expression
(log rank, P = 0.03; Figure 4). In accordance with
the survival data, a trend for a shorter relapse-free
interval was found for FSH-R-positive patients
(P = 0.734). Cox regression analysis showed both
receptors to be independent prognostic markers for
patient survival [LH-R, P = 0.026, 95% confidence
interval (CI) 0.349–0.937; FSH-R, P = 0.015, 95%
CI 1.139–3.286] Table 4).
The results of this study show high levels of
expression of LH-R (64.3%) and FSH-R (63.1%) in
ovarian cancer tissue, with a certain amount of
variability for different histological subtypes, grades
or stages. In a study in 30 ovarian carcinomas, Zheng
et al.2 found a FSH-R positivity in 50% of all samples
according to IHC staining. Similar results were gained
with reverse transcription polymerase chain reaction
(60%) and in situ hybridization (53%); the results
obtained with all three methods correlated signifi-
cantly. Our results gained with the IHC method in a
large patient group are in good agreement with these
data.
In-vitro analyses have shown various effects of LH
and FSH on the proliferation, apoptosis and invasion
of ovarian cancer and surface epithelium cells, includ-
ing partially contradictory results.2,3 Li et al.4 observed
concentration-dependent growth induction with FSH
using the FSH-R3. Moreover, in-vitro models employ-
ing ovarian cancer cell lines showed opposing effects
of FSH and LH on cell stimulation, namely a blockage
of FSH stimulation by LH. Therefore, receptor up-
regulation and down-regulation may also play a role
in this antagonism, which would be in agreement
with our IHC results. Besides the correlation of LH-R
and FSH-R expression in ovarian cancer tissue, we
additionally demonstrated that patient survival differs
significantly between those with tumours that express
solely LH-R and those with tumours that express


















LH- and FSH-receptor expression
Only FSH-R positive 
Only LH-R positive 
FSH-R equal to LH-R expression
P = 0.030 
Figure 4. Kaplan–Meier analysis indicating survival in subgroups of
patients with or without expression of luteinizing hormone receptor
(LH-R) or follicle-stimulating hormone receptor (FSH-R).








FIGO I versus II 0.989 1.009 0.301 3.385
FIGO I versus III <0.001 3.968 1.918 8.209
FIGO I versus IV 0.981 0.000 0.000
Grading 0.069
Grading 1 versus 2 0.189 1.532 0.811 2.894
Grading 1 versus 3 0.022 2.075 1.109 3.882
LH-receptor 0.026 0.572 0.349 0.937
FSH-receptor 0.015 1.935 1.139 3.286
Significant results are shown in bold.
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human chorionic gonadotropin (hCG)–doxorubicin on
ovarian cancer cells, and observed increased activity of
doxorubicin when it was conjugated to hCG through
binding to the LH receptor. Thus, new therapeutic
agents such as lytic peptides or chemotherapeutic
agents that bind to FSH-R or LH-R may offer less
toxic, but effective and selective, anticancer treatment
options.
In conclusion, LH-R and FSH-R are frequently
expressed in ovarian cancer tissue. Both receptors have
prognostic significance and may assist in the choice of
adjuvant treatment. As they are quite specific for
ovarian tissue, they can serve as targets for new cancer
therapies.
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